论文部分内容阅读
重型病毒性肝炎病情危重,病死率高,临床上无特效治疗方法。尽管目前广泛采用综合治疗方法即保肝、降酶、退黄、促进肝细胞再生、免疫治疗和支持疗法等,病死率仍高达48.8％。我院于1997年10月～1999年3月在综合治疗基础上,加用胸腺肽α_1(Tα_1)治疗重型肝炎16例,现将结果总结如下。1 资料与方法1.1 病例选择 病例选自1997年10月～1999年3月收住我科的重型肝炎患者32例。随机分为治疗组和对照组,治疗组16例,年龄21～66岁,平均38.87±14.81岁,临床早期2例,中期6例,晚期8例,并发腹水14例,并发感染10例(包括SBP4例,肺炎4例,败血症1例,胆囊炎1例);对照组16例,年龄21～70岁,平均40.81±14.18岁,临床早期4例,中期7例,
Severe viral hepatitis critical illness, high mortality, no specific clinical treatment. Despite the widespread use of integrated therapies that protect liver, reduce enzyme, revert to yellow, promote liver cell regeneration, immunotherapy and supportive therapy, the mortality rate is still as high as 48.8%. Our hospital from October 1997 to March 1999 on the basis of comprehensive treatment, plus thymosin α_1 (Tα_1) treatment of 16 cases of severe hepatitis, the results are summarized as follows. 1 Materials and Methods 1.1 Case Selection Case selected from October 1997 to March 1999 admitted to our department of 32 patients with severe hepatitis. Randomly divided into treatment group and control group, the treatment group of 16 patients aged 21 to 66 years old, with an average of 38.87 ± 14.81 years, 2 cases early clinical, 6 cases in the middle and late in 8 cases, 14 cases complicated with ascites and 10 cases of infection (including 4 cases of SBP, 1 case of pneumonia, 1 case of sepsis and 1 case of cholecystitis). The control group, 16 cases, aged 21-70 years (average 40.81 ± 14.18 years), 4 cases of early clinical stage, 7 cases of middle stage,